173 related articles for article (PubMed ID: 26582128)
1. Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model.
Fichou N; Gouard S; Maurel C; Barbet J; Ferrer L; Morgenstern A; Bruchertseifer F; Faivre-Chauvet A; Bigot-Corbel E; Davodeau F; Gaschet J; Chérel M
Front Med (Lausanne); 2015; 2():76. PubMed ID: 26582128
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy.
Gouard S; Pallardy A; Gaschet J; Faivre-Chauvet A; Bruchertseifer F; Morgenstern A; Maurel C; Matous E; Kraeber-Bodéré F; Davodeau F; Chérel M
Nucl Med Biol; 2014 May; 41 Suppl():e30-5. PubMed ID: 24759272
[TBL] [Abstract][Full Text] [Related]
3. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
[TBL] [Abstract][Full Text] [Related]
4. Targeted-Alpha-Therapy Combining Astatine-211 and anti-CD138 Antibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma Minimal Residual Disease.
Gouard S; Maurel C; Marionneau-Lambot S; Dansette D; Bailly C; Guérard F; Chouin N; Haddad F; Alliot C; Gaschet J; Eychenne R; Kraeber-Bodéré F; Chérel M
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32971984
[TBL] [Abstract][Full Text] [Related]
5. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
6. What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between
Bailly C; Gouard S; Guérard F; Chalopin B; Carlier T; Faivre-Chauvet A; Remaud-Le Saëc P; Bourgeois M; Chouin N; Rbah-Vidal L; Tripier R; Haddad F; Kraeber-Bodéré F; Bodet-Milin C; Chérel M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137758
[TBL] [Abstract][Full Text] [Related]
7. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Efficacy of Alpha-RIT Using a (213)Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis.
Derrien A; Gouard S; Maurel C; Gaugler MH; Bruchertseifer F; Morgenstern A; Faivre-Chauvet A; Classe JM; Chérel M
Front Med (Lausanne); 2015; 2():88. PubMed ID: 26734610
[TBL] [Abstract][Full Text] [Related]
9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma.
Supiot S; Faivre-Chauvet A; Couturier O; Heymann MF; Robillard N; Kraeber-Bodéré F; Morandeau L; Mahé MA; Chérel M
Cancer; 2002 Feb; 94(4 Suppl):1202-9. PubMed ID: 11877746
[TBL] [Abstract][Full Text] [Related]
12. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
13. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
14. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Immuno-PET of CD138 and PET imaging with
Bailly C; Gouard S; Lacombe M; Remaud-Le Saëc P; Chalopin B; Bourgeois M; Chouin N; Tripier R; Halime Z; Haddad F; Faivre-Chauvet A; Kraeber-Bodéré F; Chérel M; Bodet-Milin C
Oncotarget; 2018 Feb; 9(10):9061-9072. PubMed ID: 29507674
[TBL] [Abstract][Full Text] [Related]
16. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
17. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors.
Rousseau C; Ruellan AL; Bernardeau K; Kraeber-Bodéré F; Gouard S; Loussouarn D; Saï-Maurel C; Faivre-Chauvet A; Wijdenes J; Barbet J; Gaschet J; Chérel M; Davodeau F
EJNMMI Res; 2011 Sep; 1(1):20. PubMed ID: 22214534
[TBL] [Abstract][Full Text] [Related]
18. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model.
Muselaers CH; Oosterwijk E; Bos DL; Oyen WJ; Mulders PF; Boerman OC
Mol Imaging; 2014; 13():1-7. PubMed ID: 24824962
[TBL] [Abstract][Full Text] [Related]
19. Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.
Ménager J; Gorin JB; Maurel C; Drujont L; Gouard S; Louvet C; Chérel M; Faivre-Chauvet A; Morgenstern A; Bruchertseifer F; Davodeau F; Gaschet J; Guilloux Y
PLoS One; 2015; 10(6):e0130249. PubMed ID: 26098691
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
